Molecular data
| Molecular formula | C221H342N50O68 |
|---|---|
| Molecular weight | 4731.32 Da |
| Sequence | GLP-3 RT (LY3437943) — synthetic triagonist peptide; full sequence not disclosed on page |
| Sequence length | 39 residues |
| CAS / identifier | LY3437943 (CAS 2381089-83-2) |
| Physical form | Lyophilized powder |
| Available sizes | 10mg, 15mg, 24mg, 30mg, 48mg, 60mg |
How it works
GLP-1 Receptor Agonism
Activates GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress glucagon release, delay gastric emptying, and engage central appetite regulation pathways in the hypothalamus. This is the same pathway targeted by semaglutide and liraglutide.
- Glucose-dependent insulin secretion
- Delayed gastric emptying
- Central appetite suppression
GIP Receptor Agonism
Co-agonism at GIP receptors potentiates the metabolic effects of GLP-1 signaling, enhances lipid metabolism, and modulates adipose tissue remodeling. This dual GLP-1/GIP mechanism is shared with tirzepatide, but GLP-3 RT adds a third target.
- Synergistic insulin potentiation
- Lipid metabolism enhancement
- Adipose tissue signaling
Glucagon Receptor Agonism
The unique third target — glucagon receptor activation increases hepatic energy expenditure, promotes fatty acid oxidation, and drives thermogenesis. This differentiates GLP-3 RT from all dual agonists and may account for its superior weight reduction in trials.
- Hepatic energy expenditure increase
- Enhanced fatty acid oxidation
- Thermogenic pathway activation
What the research shows
Obesity & Weight Management
GLP-3 RT demonstrated up to 24.2% body weight reduction at 48 weeks in the Phase 2 obesity trial — the largest reduction reported for any anti-obesity compound in a randomized trial at that time.
Jastreboff et al. 2023
Type 2 Diabetes
In subjects with T2DM, GLP-3 RT reduced HbA1c by up to 2.16% and fasting glucose by up to 69.1 mg/dL, with weight loss up to 16.94% — exceeding most dual-agonist results in comparable populations.
Panou et al. 2026
Liver Fat Reduction (MASLD/MASH)
GLP-3 RT has shown marked reductions in liver fat content in preclinical and early clinical data, positioning it as a candidate for metabolic dysfunction-associated steatotic liver disease research.
Malandris et al. 2026
Triple vs Dual Agonism
Network meta-analysis shows GLP-3 RT achieved the largest weight loss and HbA1c reduction among all glucagon receptor agonists studied, surpassing survodutide, mazdutide, and cotadutide.
Abulehia et al. 2026
Specification
| Compound Class | Triple GLP-1/GIP/Glucagon receptor agonist |
|---|---|
| Research Name | LY3437943 (GLP-3 RT) |
| Targets | GLP-1R + GIPR + GCGR |
| Form | Lyophilized powder |
| Purity | ≥99% (HPLC verified) |
| Testing | Third-party HPLC, Mass Spec, Endotoxin |
| Storage (lyophilized) | -20°C for long-term stability |
| Storage (reconstituted) | 2–8°C, use within 14 days |
| Solubility | Bacteriostatic water for reconstitution |
| COA | Included with every order |
| Stability | 24 months from manufacture date when stored properly |
| Appearance | White to off-white powder |
| Molecular Formula | Available on request |
Frequently asked questions
What is GLP-3 RT?
GLP-3 RT (LY3437943) is a first-in-class triple hormone receptor agonist. It simultaneously targets three receptors: GLP-1 (appetite and insulin), GIP (metabolic potentiation), and glucagon (energy expenditure). This triple mechanism distinguishes it from single-agonists like semaglutide and dual-agonists like tirzepatide.
How does GLP-3 RT differ from semaglutide and tirzepatide?
Semaglutide (Ozempic/Wegovy) targets GLP-1 only. Tirzepatide (Mounjaro/Zepbound) targets GLP-1 + GIP (dual agonist). GLP-3 RT targets GLP-1 + GIP + Glucagon (triple agonist). In the Phase 2 trial, GLP-3 RT achieved 24.2% body weight reduction at 48 weeks — higher than any published result for semaglutide (~15%) or tirzepatide (~22%) at comparable timepoints.
What were the key Phase 2 trial results?
In the Jastreboff et al. 2023 NEJM trial (n=338, 48 weeks): the 12mg dose produced 24.2% mean body weight reduction. 92% of participants lost ≥5% body weight, 75% lost ≥10%, and 60% lost ≥15%. The effect was dose-dependent, with even the 1mg dose achieving 8.7% reduction.
Is GLP-3 RT FDA approved?
No. GLP-3 RT is currently in Phase 3 clinical trials (the TRIUMPH program). GLP-3 RT is a research compound sold exclusively for in vitro laboratory research. It is not FDA approved and should not be confused with approved medications.
How should GLP-3 RT be stored?
Store lyophilized at -20°C for long-term stability. After reconstitution with bacteriostatic water, refrigerate at 2-8°C and use within 14 days. Protect from direct light and avoid repeated freeze-thaw cycles.
Literature
- NEJM Triple-Hormone-Receptor Agonist GLP-3 RT for Obesity — A Phase 2 Trial
- Review GLP-3 RT in type 2 diabetes mellitus and obesity: an overview
- Meta-Analysis Comparative Efficacy and Safety of Glucagon Receptor Agonists: A Network Meta-Analysis
- Preclinical GLP-3 RT Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models
For laboratory research use only. Not a drug, supplement, or medical product; not for human or animal use. All findings referenced are from published preclinical/laboratory research.